Medicare Enrolled
Dr. Kanwaldeep Rasila, M.D.
Hematology & Oncology · Fairfield, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rasila from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rasila?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rasila
Dr. Kanwaldeep Rasila is a hematology & oncology specialist in Fairfield, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Rasila performed 1,064 Medicare services across 627 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rasila received a total of $5,903 from 52 pharmaceutical and/or device companies across 214 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rasila is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 49% volume in CA
$5,903 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,064
Medicare services
Top 49% in CA for hematology & oncology
627
Unique beneficiaries
$102
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~59 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
319 | $72 | $222 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
271 | $94 | $342 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
173 | $159 | $439 |
| New patient office visit, complex (60-74 min) | 62 | $194 | $579 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
59 | $108 | $347 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
40 | $14 | $76 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
39 | $157 | $585 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
32 | $117 | $412 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
22 | $68 | $244 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
17 | $77 | $163 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
16 | $8 | $15 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
14 | $44 | $145 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.1% high complexity
3.8% medium
94.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,903
Total received (2019-2024)
Avg $1,181/year across 5 years
Top 41% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
52
Companies
214
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,110 (86.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$430 (7.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$363 (6.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,938
2023
$3,173
2022
$725
2021
$57
2019
$12
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$237
Merck Sharp & Dohme LLC
$230
PFIZER INC.
$171
AstraZeneca Pharmaceuticals LP
$159
E.R. Squibb & Sons, L.L.C.
$111
Lilly USA, LLC
$98
SpringWorks Therapeutics, Inc.
$83
Celgene Corporation
$73
ABBVIE INC.
$71
Janssen Biotech, Inc.
$67
ARRAY BIOPHARMA INC
$63
GENZYME CORPORATION
$54
Genmab U.S., Inc.
$53
Eisai Inc.
$47
Takeda Pharmaceuticals U.S.A., Inc.
$46
JAZZ PHARMACEUTICALS INC.
$41
Stemline Therapeutics Inc.
$33
Ipsen Biopharmaceuticals, Inc
$31
Genentech USA, Inc.
$30
Astellas Pharma US Inc
$27
Regeneron Healthcare Solutions, Inc.
$26
Kyowa Kirin, Inc.
$26
Alexion Pharmaceuticals, Inc.
$26
Daiichi Sankyo Inc.
$25
Acrotech Biopharma Inc.
$25
EMD Serono, Inc.
$21
BeiGene USA, Inc.
$19
Incyte Corporation
$19
RECORDATI_RARE_DISEASES_INC.
$15
Emmaus Medical, Inc.
$10
Top 3 companies account for 32.9% of 2024 payments
All-time payments by company (2019-2024) ›
GlaxoSmithKline, LLC.
$546
Merck Sharp & Dohme LLC
$496
Novartis Pharmaceuticals Corporation
$452
PFIZER INC.
$436
E.R. Squibb & Sons, L.L.C.
$394
AstraZeneca Pharmaceuticals LP
$268
Novocure GmbH
$250
Celgene Corporation
$232
Myriad Genetic Laboratories, Inc.
$205
Genentech USA, Inc.
$192
GENZYME CORPORATION
$185
Lilly USA, LLC
$177
ABBVIE INC.
$138
Janssen Biotech, Inc.
$133
ARRAY BIOPHARMA INC
$126
Eisai Inc.
$118
Stemline Therapeutics Inc.
$97
Regeneron Healthcare Solutions, Inc.
$86
SpringWorks Therapeutics, Inc.
$83
Genmab U.S., Inc.
$77
TAIHO ONCOLOGY, INC.
$73
Mirati Therapeutics, Inc.
$70
Kite Pharma, Inc.
$69
Takeda Pharmaceuticals U.S.A., Inc.
$68
SERVIER PHARMACEUTICALS LLC
$67
Astellas Pharma US Inc
$61
Pharmacyclics LLC, An AbbVie Company
$52
Kyowa Kirin, Inc.
$49
Alexion Pharmaceuticals, Inc.
$46
Foundation Medicine, Inc.
$44
Seagen Inc.
$42
Coherus Biosciences Inc.
$41
JAZZ PHARMACEUTICALS INC.
$41
Janssen Pharmaceuticals, Inc
$41
G1 Therapeutics, Inc.
$40
Organon LLC
$32
Emmaus Medical, Inc.
$31
Ipsen Biopharmaceuticals, Inc
$31
Octapharma USA, Inc.
$30
RECORDATI_RARE_DISEASES_INC.
$28
CTI BioPharma Corp.
$26
SOBI, INC
$26
Boehringer Ingelheim Pharmaceuticals, Inc.
$25
Daiichi Sankyo Inc.
$25
Acrotech Biopharma Inc.
$25
AVEO Pharmaceuticals, Inc.
$23
Sirtex Medical Inc
$21
EMD Serono, Inc.
$21
BeiGene USA, Inc.
$19
Incyte Corporation
$19
Amgen Inc.
$17
Gilead Sciences, Inc.
$12
Top 3 companies account for 25.3% of all-time payments
Associated products mentioned in payments ›
AUGTYRO · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CERDELGA · COSELA · DARZALEX · Doptelet · ELIQUIS · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Endari · Enhertu · Epkinly · FOTIVDA · Fabhalta · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · JARDIANCE · JAYPIRCA · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LONSURF · LORBRENA · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · OGSIVEO · ONTRUZANT · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · Orserdu · PANHEMATIN · PANZYGA · PIQRAY · PRECISETUMOR · PROMACTA · Phesgo · Pomalyst · Poteligeo · REBLOZYL · RYBREVANT · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SYLVANT · TAGRISSO · TECVAYLI · TIVDAK · TUKYSA · Tecentriq · Tibsovo · ULTOMIRIS · Udenyca · VENCLEXTA · VERQUVO · VERZENIO · VPRIV · Venclexta · Vonjo · XARELTO · XTANDI · Xospata · Yescarta · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (87%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
59
Per 100K population
13.1
County median income
$99,994
Nearest hospital
NORTHBAY MEDICAL CENTER
6.6 mi
6.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rasila is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rasila experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Rasila performed 319 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rasila receive payments from pharmaceutical companies?
Yes. Dr. Rasila received a total of $5,903 from 52 companies across 214 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rasila's costs compare to other hematology & oncology specialists in Fairfield?
Dr. Rasila's average Medicare payment per service is $102. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rasila) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Fairfield
Browse hematology & oncology specialists in Fairfield ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology